Nanomaterials for cancer treatment: A scientometric analysis
DOI:
https://doi.org/10.18041/2619-4465/interfaces.2.13405Palavras-chave:
Nanomateriales, Tratamiento del cáncer, Análisis cienciométrico, Entrega de fármacos, NanotecnologíaResumo
El uso de nanomateriales ha surgido como una herramienta potencial en la terapia contra el cáncer dada su capacidad para dirigirse selectivamente a las células cancerosas, ofreciendo una entrega dirigida de fármacos, toxicidad reducida y eficacia mejorada, lo que puede mejorar la supervivencia y la calidad de vida. Sin embargo, existen desafíos generales en el tema académico con respecto a la biocompatibilidad y la traducción clínica. La investigación en curso sugiere que los nanomateriales contribuirán a mejorar el tratamiento del cáncer en términos de viabilidad y ensayos clínicos. Por otro lado, también existe un vacío en el aspecto cienciométrico de este campo de investigación, ya que existen principalmente artículos experimentales y algunas revisiones sobre el lado científico y biológico del campo, que no ofrecen información profunda sobre los patrones de publicación, los puntos críticos de investigación o las redes de colaboración típicas de los estudios cienciométricos. Por lo tanto, este trabajo ofrece un análisis cienciométrico con perspectivas valiosas sobre el panorama global de este campo.
Downloads
Referências
[1]X. Cheng, Q. Xie, and Y. Sun, “Advances in nanomaterial-based targeted drug delivery systems,” Front. Bioeng. Biotechnol., vol. 11, p. 1177151, Apr. 2023.
[2]X. Hao, J. Wu, D. Xiang, and Y. Yang, “Recent Advance of Nanomaterial-Mediated Tumor Therapies in the Past Five Years,” Front. Pharmacol., vol. 13, p. 846715, Feb. 2022.
[3]L. Tang et al., “Versatile carbon nanoplatforms for cancer treatment and diagnosis: strategies, applications and future perspectives,” Theranostics, vol. 12, no. 5, pp. 2290–2321, Feb. 2022.
[4]A. Ojha, S. Jaiswal, P. Bharti, and S. K. Mishra, “Nanoparticles and Nanomaterials-Based Recent Approaches in Upgraded Targeting and Management of Cancer: A Review,” Cancers, vol. 15, no. 1, p. 162, Dec. 2022.
[5]B. Wirthl, P. Decuzzi, B. A. Schrefler, and W. A. Wall, “Computational modelling of cancer nanomedicine: Integrating hyperthermia treatment into a multiphase porous-media tumour model,” Feb. 03, 2025. Accessed: Jul. 08, 2025. [Online]. Available: http://arxiv.org/abs/2502.01248
[6]A. A. Demessie et al., “An Advanced Thermal Decomposition Method to Produce Magnetic Nanoparticles with Ultrahigh Heating Efficiency for Systemic Magnetic Hyperthermia,” Small Methods, vol. 6, no. 12, p. 2200916, Dec. 2022.
[7]X. Yin, Z. He, W. Ge, and Z. Zhao, “Application of aptamer functionalized nanomaterials in targeting therapeutics of typical tumors,” Front. Bioeng. Biotechnol., vol. 11, p. 1092901, Feb. 2023.
[8]N. Krasteva and M. Georgieva, “Promising Therapeutic Strategies for Colorectal Cancer Treatment Based on Nanomaterials,” Pharmaceutics, vol. 14, no. 6, p. 1213, Jun. 2022.
[9]I. A. F. Urquizo et al., “Effect of aminosilane nanoparticle coating on structural and magnetic properties and cell viability in human cancer cell lines,” Part. Part. Syst. Charact., vol. 39, no. 10, p. 2200106, Oct. 2022.
[10]J. A. Uribe-Calderon, C. G. Poot-Bote, J. M. Cervantes-Uc, E. L. Pacheco-Pantoja, I. Echevarría-Machado, and N. Rodríguez-Fuentes, “Physicochemical and biological characterization of oxidized multi-walled carbon nanotubes on HepG2 liver cells,” J. Nanopart. Res., vol. 24, no. 7, Jul. 2022, doi: 10.1007/s11051-022-05489-1.
[11]A. R. Lazo-Fraga, M. Resina-Gallego, X. Lou, M. Valiente-Malmagro, and M. Villanueva-Tagle, “Sponge-loaded spion for adsorption of trans-[CuCl2(NH3)2] in wastewater remediation,” Mater. Today Commun., vol. 40, no. 110176, p. 110176, Aug. 2024.
[12]L. S. Santos, M. Z. Tonel, M. O. Martins, and C. L. dos Santos, “Theoretical exploration of chitosan nanoparticles associated with platinum compounds for cancer treatment: Insights from DFT and molecular docking analyses,” Bionanoscience, vol. 15, no. 1, Mar. 2025, doi: 10.1007/s12668-024-01728-y.
[13]J. de Lara Andrade et al., “Multifunctional nanoplatforms based on alumina-coated mesoporous silica with potential for cancer theranostics applications,” Microporous Mesoporous Mater., vol. 382, no. 113373, p. 113373, Jan. 2025.
[14]A. A. P. Mansur, J. C. Amaral-Júnior, S. M. Carvalho, I. C. Carvalho, and H. S. Mansur, “Cu-In-S/ZnS@carboxymethylcellulose supramolecular structures: Fluorescent nanoarchitectures for targeted-theranostics of cancer cells,” Carbohydr Polym, vol. 247, p. 116703, Nov. 2020.
[15]S. Kumar et al., “Designed ultrafine polymer-coated manganese-cobalt ferrite nanoparticles loaded with anticancer drug: efficacy enhancement through host:guest complexation on the polymer surface,” J. Macromol. Sci. Part A Pure Appl. Chem., vol. 60, no. 8, pp. 580–590, Aug. 2023.
[16]A. Saravanan et al., “A review on synthesis methods and recent applications of nanomaterial in wastewater treatment: Challenges and future perspectives,” Chemosphere, vol. 307, no. Pt 1, p. 135713, Nov. 2022.
[17]D. Mundekkad and W. C. Cho, “Nanoparticles in Clinical Translation for Cancer Therapy,” International Journal of Molecular Sciences, vol. 23, no. 3, p. 1685, Feb. 2022.
[18]M. A. Annunziato, “Challenges of clinical research in nanomedicine in Venezuela and Latin America,” 2015, Unpublished. doi: 10.13140/RG.2.2.16745.36969/1.
[19]O. Gutiérrez Coronado et al., “Functionalized Nanomaterials in Cancer Treatment: A Review,” International Journal of Molecular Sciences, vol. 26, no. 6, p. 2633, Mar. 2025.
[20]N. L. Ndlovu, W. B. Mdlalose, B. Ntsendwana, and T. Moyo, “Evaluation of Advanced Nanomaterials for Cancer Diagnosis and Treatment,” Pharmaceutics, vol. 16, no. 4, p. 473, Mar. 2024.
[21]Z. Cheng, M. Li, R. Dey, and Y. Chen, “Nanomaterials for cancer therapy: current progress and perspectives,” Journal of Hematology & Oncology, vol. 14, no. 1, pp. 1–27, May 2021.
[22]P. N. Navya, A. Kaphle, S. P. Srinivas, S. K. Bhargava, V. M. Rotello, and H. K. Daima, “Current trends and challenges in cancer management and therapy using designer nanomaterials,” Nano Convergence, vol. 6, no. 1, pp. 1–30, Jul. 2019.
[23]“Recent advances in dual- and multi-responsive nanomedicines for precision cancer therapy,” Biomaterials, vol. 291, p. 121906, Dec. 2022.
[24]P. Tan, X. Chen, H. Zhang, Q. Wei, and K. Luo, “Artificial intelligence aids in development of nanomedicines for cancer management,” Semin Cancer Biol, vol. 89, pp. 61–75, Feb. 2023.
[25]N. P. Koyande, R. Srivastava, A. Padmakumar, and A. K. Rengan, “Advances in Nanotechnology for Cancer Immunoprevention and Immunotherapy: A Review,” Vaccines (Basel), vol. 10, no. 10, Oct. 2022, doi: 10.3390/vaccines10101727.
[26]S. A. Mir et al., “Role of Nanotechnology in Overcoming the Multidrug Resistance in Cancer Therapy: A Review,” Molecules, vol. 27, no. 19, Oct. 2022, doi: 10.3390/molecules27196608.
[27]P. Singh et al., “Global research and current trends on nanotherapy in lung cancer research: a bibliometric analysis of 20 years,” Discover Oncology, vol. 15, no. 1, pp. 1–18, Oct. 2024.
[28]“Current perspectives and trend of nanomedicine in cancer: A review and bibliometric analysis,” Journal of Controlled Release, vol. 352, pp. 211–241, Dec. 2022.
[29]Y. Zhao et al., “Bibliometric analysis of single-cell sequencing researches on immune cells and their application of DNA damage repair in cancer immunotherapy,” Front. Oncol., vol. 13, p. 1067305, Jan. 2023.
[30]R. Pranckutė, “Web of Science (WoS) and Scopus: The titans of bibliographic information in today’s academic world,” Publications, vol. 9, no. 1, p. 12, Mar. 2021.
[31]S. Robledo, L. Valencia, M. Zuluaga, O. A. Echeverri, and J. W. A. Valencia, “tosr: Create the Tree of Science from WoS and Scopus,” J. Sci. Res., vol. 13, no. 2, pp. 459–465, Aug. 2024.
[32]“Attention decay in science,” Journal of Informetrics, vol. 9, no. 4, pp. 734–745, Oct. 2015.
[33]M. V. Simkin and V. P. Roychowdhury, “A mathematical theory of citing,” Journal of the American Society for Information Science and Technology, vol. 58, no. 11, pp. 1661–1673, Sep. 2007.
[34]“Website.” [Online]. Available: https://doi.org/10.1016/j.joi.2015.07.006.
[35]J. Marton, “Obsolescence or immediacy? Evidence supporting Price’s hypothesis,” Scientometrics, vol. 7, no. 3, pp. 145–153, Mar. 1985.
[36]D.-W. Zheng et al., “Switching Apoptosis to Ferroptosis: Metal-Organic Network for High-Efficiency Anticancer Therapy,” Nano Lett, vol. 17, no. 1, pp. 284–291, Jan. 2017.
[37]Y. Jiang, J. Li, X. Zhen, C. Xie, and K. Pu, “Dual-Peak Absorbing Semiconducting Copolymer Nanoparticles for First and Second Near-Infrared Window Photothermal Therapy: A Comparative Study,” Adv Mater, vol. 30, no. 14, p. e1705980, Apr. 2018.
[38]R. Xing, Q. Zou, C. Yuan, L. Zhao, R. Chang, and X. Yan, “Self-Assembling Endogenous Biliverdin as a Versatile Near-Infrared Photothermal Nanoagent for Cancer Theranostics,” Adv Mater, vol. 31, no. 16, p. e1900822, Apr. 2019.
[39]B. Niu et al., “Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy,” Biomaterials, vol. 277, p. 121110, Oct. 2021.
[40]W. Cheng et al., “Preparation and performance analysis of zinc-iron-based nanomaterials for targeted transport,” Biomed Mater Eng, vol. 36, no. 1, pp. 3–14, Jan. 2025.
[41]M. C. Chung et al., “Multi-Step Assembly of an RNA-Liposome Nanoparticle Formulation Revealed by Real-Time, Single-Particle Quantitative Imaging,” Adv Sci (Weinh), vol. 12, no. 12, p. e2414305, Mar. 2025.
[42]S. M. Carvalho, A. A. P. Mansur, Z. I. P. Lobato, M. F. Leite, and H. S. Mansur, “Bioengineering chitosan-antibody/fluorescent quantum dot nanoconjugates for targeted immunotheranostics of non-hodgkin B-cell lymphomas,” Int J Biol Macromol, vol. 294, p. 139515, Mar. 2025.
[43]P. Gong et al., “Fluorescent COFs with a Highly Conjugated Structure for Combined Starvation and Gas Therapy,” ACS Appl Mater Interfaces, vol. 14, no. 41, pp. 46201–46211, Oct. 2022.
[44]X. Chen, H. Gao, Y. Deng, Q. Jin, J. Ji, and D. Ding, “Supramolecular Aggregation-Induced Emission Nanodots with Programmed Tumor Microenvironment Responsiveness for Image-Guided Orthotopic Pancreatic Cancer Therapy,” ACS Nano, vol. 14, no. 4, pp. 5121–5134, Apr. 2020.
[45]S.-R. Li, S.-Y. Tao, Q. Li, C.-Y. Hu, and Z.-J. Sun, “Harnessing nanomaterials for copper-induced cell death,” Biomaterials, vol. 313, p. 122805, Feb. 2025.
[46]R. Zhao et al., “Nanomaterial-Based Organelles Protect Normal Cells against Chemotherapy-Induced Cytotoxicity,” Adv Mater, vol. 30, no. 27, p. e1801304, Jul. 2018.
[47]M. Rossetti et al., “Engineering DNA‐grafted quatsomes as stable nucleic acid‐responsive fluorescent nanovesicles,” Adv. Funct. Mater., vol. 31, no. 46, p. 2103511, Nov. 2021.
[48]Y. Zheng et al., “Acid-Unlocked Two-Layer Ca-Loaded Nanoplatform to Interfere With Mitochondria for Synergistic Tumor Therapy,” Int J Nanomedicine, vol. 20, pp. 1899–1920, Feb. 2025.
[49]D. K. Korir et al., “Facile Photochemical Syntheses of Conjoined Nanotwin Gold-Silver Particles within a Biologically-Benign Chitosan Polymer,” Nanomaterials (Basel), vol. 9, no. 4, Apr. 2019, doi: 10.3390/nano9040596.
[50]V. J. X. Phua et al., “Nanomaterial Probes for Nuclear Imaging,” Nanomaterials (Basel), vol. 12, no. 4, Feb. 2022, doi: 10.3390/nano12040582.
[51]J. Liu, R. Zhang, and Z. P. Xu, “Nanoparticle-Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions,” Small, vol. 15, no. 32, p. e1900262, Aug. 2019.
[52]C. Liang et al., “Supramolecular Nanofibers of Drug-Peptide Amphiphile and Affibody Suppress HER2+ Tumor Growth,” Adv Healthc Mater, vol. 7, no. 22, p. e1800899, Nov. 2018.
[53]M.-Z. Cai et al., “Peptide-based fluorescent probes for the diagnosis of tumor and image-guided surgery,” Biosens Bioelectron, vol. 276, p. 117255, May 2025.
[54]A. Norouzi, P. Parsaei-Mohammadi, F. Zare-Farashbandi, E. Zare-Farashbandi, and E. Geraei, “H-index and research evaluation: A suggested set of components for developing a comprehensive author-level index,” Journal of Information Science, doi: 10.1177/01655515241293761.
[55]Y. Zhao and R. Zhao, “An evolutionary analysis of collaboration networks in scientometrics,” Scientometrics, vol. 107, no. 2, pp. 759–772, Feb. 2016.
[56]N. Wahid, N. F. Warraich, and M. Tahira, “Group level scientometric analysis of Pakistani authors,” COLLNET Journal of Scientometrics and Information Management, pp. 287–304, Nov. 2021.
[57]“What makes an informative and publication-worthy scientometric analysis of literature: A guide for authors, reviewers and editors,” Transportation Research Interdisciplinary Perspectives, vol. 22, p. 100956, Nov. 2023.
[58]T. Bergmann, R. Dale, N. Sattari, E. Heit, and H. S. Bhat, “The Interdisciplinarity of Collaborations in Cognitive Science,” Cognitive Science, vol. 41, no. 5, pp. 1412–1418, Jul. 2017.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2025 Interfaces
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
